FDA Psychedelics Hearing Focuses On Boosting Therapeutic Innovations While Adhering To Scientific Standards

FDA Psychedelics Hearing Focuses On Boosting Therapeutic Innovations While Adhering To Scientific Standards

The Food and Drug Administration (FDA) hosted a hearing on psychedelic therapy on Monday, with the agency and other federal partners that participated taking testimony from dozens of advocates, researchers and industry participants. Eighty invited witnesses were given two minutes each to briefly summarize their stances and flag issues for federal officials. Prior to the […]

Experts urge FDA to set clear safety and access standards for ...

As Trump backs psychedelics research, FDA weighs safety and access standards

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

FDA psychedelics hearing tackles questions about treatments

Psychedelic compounds like LSD and psilocybin (the active ingredient in magic mushrooms) have seen renewed interest for their therapeutic potential. In April, President Donald Trump signed an executive order aimed…

No Questions Asked: FDA’s Psychedelics Public Hearing

Yesterday, some three hundred people convened at FDA’s White Oak Campus in Maryland, on the outskirts of Washington, D.C., to participate in the agency’s four-hour public hearing concerning the potential future therapeutic use of psychedelic drugs. A further one thousand viewers tuned in to a live stream.

FDA psychedelics hearing draws little pushback on future therapeutic use

Few voices rose against psychedelic therapies at the Food and Drug Administration’s public hearing on Monday.